Compare Citius Pharmaceuticals Inc (CTXR) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Deckers Outdoor Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Deckers Outdoor Corp trades at $94.19 (market cap $13.27B). The key difference: Deckers Outdoor Corp is far larger — about 708.5× Citius Pharmaceuticals Inc's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | DECK | |
|---|---|---|
Market Cap | $18.73M | $13.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $123.91 |
52-Week Low | $0.48 | $79.54 |
Enterprise Value | $14.95M | $12.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Deckers Outdoor (DECK) trades at $97.46, down 0.42% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $0.96 beating expectations of $0.81. Revenue grew to $4.99 billion in 2025 with impressive 18.36% net margin and 42.56% ROE. Analyst consensus remains positive with 45% buy ratings and $122.40 price target, though recent guidance concerns caused a 6% selloff.
DECK offers compelling value with a 13.86 P/E ratio below industry averages, supported by HOKA and UGG brand strength. Key risks include tariff headwinds, brand concentration, and execution challenges. The stock presents a growth opportunity at current levels but faces near-term volatility from macroeconomic pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
